Statin Therapy and the Risk of Osteoporotic Fractures in Patients with Metabolic Syndrome: a Nested Case-Control Study
- Authors
- Kim, Kyoung Jin; Choi, Jimi; Kim, Ji Yoon; Bae, Jae Hyun; Kim, Kyeong Jin; Kim, Hee Young; Yoo, Hye Jin; Seo, Ji A; Kim, Nan Hee; Choi, Kyung Mook; Baik, Sei Hyun; Kim, Sin Gon; Kim, Nam Hoon
- Issue Date
- Sep-2021
- Publisher
- 한국지질동맥경화학회
- Keywords
- HMG-CoA reductase inhibitor; Statin; Osteoporotic fractures; Metabolic syndrome; Case-control studies
- Citation
- Journal of Lipid and Atherosclerosis, v.10, no.3, pp 322 - 333
- Pages
- 12
- Indexed
- SCOPUS
KCI
- Journal Title
- Journal of Lipid and Atherosclerosis
- Volume
- 10
- Number
- 3
- Start Page
- 322
- End Page
- 333
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/54552
- DOI
- 10.12997/jla.2021.10.3.322
- ISSN
- 2287-2892
2288-2561
- Abstract
- Objective: We aimed to investigate the association between statin use and the risk of major osteoporotic fractures in patients with metabolic syndrome (MetS).
Methods: A nested case-control study was performed in patients with MetS (≥50 years) who had no history of osteoporotic fracture using the Korean National Health Insurance Service- Health Screening Cohort. This study included 17,041 patients diagnosed with new-onset osteoporotic fractures and controls matched in a 1:1 ratio by age, sex, body mass index, cohort entry date, and follow-up duration. Conditional logistic regression analysis was used to evaluate covariate-adjusted odds ratios (ORs) and 95% confidence intervals (CIs).
Results: During a 4-year follow-up period, the risk of major osteoporotic fractures was significantly reduced by 9% (OR, 0.91; 95% CI, 0.85–0.97) in statin users compared with that in non-users. Among subtypes of major osteoporotic fracture, a risk reduction with statin therapy was significant for vertebral fracture (OR, 0.86; 95% CI, 0.79–0.94) but not for non-vertebral fracture (OR, 0.97; 95% CI, 0.88–1.06). Longer duration (OR, 0.97; 95% CI, 0.96–0.99, per 1-year increase) and higher cumulative dose (OR, 0.97; 95% CI, 0.95–0.99, per 365 defined daily doses) of statins were negatively associated with the risk of major osteoporotic fracture.
Conclusion: This study supports the hypothesis that statin therapy has a beneficial effect on major osteoporotic fractures, especially vertebral fractures, in patients with MetS.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Endocrinology and Metabolism > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.